Levodopa-based device-aided therapies for the treatment of advanced Parkinson's disease: a social return on investment analysis.

ABSTRACT:

Introduction

Parkinson's disease (PD) is an incurable, progressive, neurodegenerative disorder. As PD advances and symptoms progress, patients become increasingly dependent on family and carers. Traditional cost-effectiveness analyses (CEA) only consider patient and payer-related outcomes, failing to acknowledge impacts on families, carers, and broader society. This novel Social Return on Investment (SROI) analysis aimed to evaluate the broader impact created by improving access to levodopa (LD) device-aided therapies (DATs) for people living with advanced PD (aPD) in Australia.

Methods

A forecast SROI analysis over a three-year time horizon was conducted. People living with aPD and their families were recruited for qualitative interviews or a quantitative survey. Secondary

SUBMITTER: Denham I 

PROVIDER: S-EPMC11228815 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature